The effects of different saddle pads on the pressure exerted on the equine back by correctly fitting dressage saddles

In order to improve saddle fit and comfort for the horse, many equestrians use a saddle pad in addition to an ordinary saddle cloth or blanket. To date, only a few scientific studies have investigated if such pads lower the magnitude of pressure exerted on the horse’s back. The results of these studies are highly variable, presumably due to the different materials of the examined pads. The present study investigated the effect of five different, commercially available saddle pads on the mean pressure, the highest mean pressure, and the loaded area below the saddle, as well as the range of motion (ROM) of the centre of pressure (COP) on the horse’s back. Electronic saddle pressure measurements were carried out with eight horses ridden by the same person, using five different pads and a thin saddle cloth as control. Saddle pressure measurements were carried out at all gaits and on both reins, using the Pliance -S system (Novel). The results revealed that all tested pads except for the gel pad significantly lowered mean pressure below the saddle (range in reduction: 0.8 to 1.8 kPA) as well as in areas with the highest mean pressure, representing pressure points (range: 2.1 to 5.8 kPA). None of the pads increased pressure. The loaded area below the saddle was decreased slightly, but not significantly, when pads were used. The effect of the pads on the ROM of the COP was inconsistent; certain pads significantly increased this variable, but only at certain gaits. This may indicate a loss of stability in the horse-rider system, but if the magnitude of the observed changes is relevant needs further investigation. The results indicate that none of the investigated pads affected mean pressure in an unfavourable way and that the thicker pads may help to reduce the pressure acting on the horse’s back

The effects of different saddle pads on the pressure exerted on the equine back by correctly fitting dressage saddles

In order to improve saddle fit and comfort for the horse, many equestrians use a saddle pad in addition to an ordinary saddle cloth or blanket. To date, only a few scientific studies have investigated if such pads lower the magnitude of pressure exerted on the horse’s back. The results of these studies are highly variable, presumably due to the different materials of the examined pads. The present study investigated the effect of five different, commercially available saddle pads on the mean pressure, the highest mean pressure, and the loaded area below the saddle, as well as the range of motion (ROM) of the centre of pressure (COP) on the horse’s back. Electronic saddle pressure measurements were carried out with eight horses ridden by the same person, using five different pads and a thin saddle cloth as control. Saddle pressure measurements were carried out at all gaits and on both reins, using the Pliance®-S system (Novel). The results revealed that all tested pads except for the gel pad significantly lowered mean pressure below the saddle (range in reduction: 0.8 to 1.8 kPA) as well as in areas with the highest mean pressure, representing pressure points (range: 2.1 to 5.8 kPA). None of the pads increased pressure. The loaded area below the saddle was decreased slightly, but not significantly, when pads were used. The effect of the pads on the ROM of the COP was inconsistent; certain pads significantly increased this variable, but only at certain gaits. This may indicate a loss of stability in the horse-rider system, but if the magnitude of the observed changes is relevant needs further investigation. The results indicate that none of the investigated pads affected mean pressure in an unfavourable way and that the thicker pads may help to reduce the pressure acting on the horse’s back

Optogenetic control of gene expression in plants in the presence of ambient white light

Optogenetics is the genetic approach for controlling cellular processes with light. It provides spatiotemporal, quantitative and reversible control over biological signaling and metabolic processes, overcoming limitations of chemically inducible systems. However, optogenetics lags in plant research because ambient light required for growth leads to undesired system activation. We solved this issue by developing plant usable light-switch elements (PULSE), an optogenetic tool for reversibly controlling gene expression in plants under ambient light. PULSE combines a blue-light-regulated repressor with a red-light-inducible switch. Gene expression is only activated under red light and remains inactive under white light or in darkness. Supported by a quantitative mathematical model, we characterized PULSE in protoplasts and achieved high induction rates, and we combined it with CRISPR–Cas9-based technologies to target synthetic signaling and developmental pathways. We applied PULSE to control immune responses in plant leaves and generated Arabidopsis transgenic plants. PULSE opens broad experimental avenues in plant research and biotechnology

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

Sattelpassform zwischen Wissenschaft und Überlieferung

Der Sattel als Schnittstelle zwischen Pferd und Reiter beeinflusst das Bewegungspotenzial des Pferdes und die Fähigkeit des Reiters, diesem harmonisch zu folgen. Unpassende Sättel führen schnell zu Rittigkeitsproblemen, Leistungsschwäche und Rückenschmerzen bei Pferd und Reiter. Wir informieren über die wesentlichen Fakten und messbare Eigenschaften bei Reitsätteln und bringen überliefertes Wissen aus dem Sattlerhandwerk damit in Einklang

Riding soundness—comparison of subjective with objective lameness assessments of owner-sound horses at trot on a treadmill

Lameness is a symptom indicative of pain or injury of the locomotor apparatus. Lame horses generally should not be ridden. However, owners’ ability to assess lameness has been questioned. This study’s aim was to use subjective lameness assessments and objective gait analysis to generate a descriptive overview of movement and weight-bearing asymmetries of owner-sound riding horses. 235 horses were subjectively assessed in a field study, and the owner’s perception of their horse’s orthopedic health was recorded through an online survey. 69 horses were re-evaluated by gait analysis at an equine hospital. During trot on an instrumented treadmill, the gait was scored by a veterinarian using lameness grades from 0/5 (sound) to 3/5 (moderate lameness visible at trot). Movement asymmetry of the head (HDmin) and pelvis (PDmin) and weight-bearing asymmetry were quantified simultaneously. The prevalence of subjectively scored lameness grade ≥2/5 in one or more limbs was 55% during study part 1 and 74% during study part 2. Movement asymmetry of the head and/or pelvis exceeding HDmin ≥12 mm and/or PDmin ≥6 mm was found in 57% of the horses. 58% showed weight-bearing asymmetries between contralateral front and/or hind limbs of ≥3% body mass. Gait analysis showed considerable variability of movement and weight-bearing asymmetry values, sometimes independent of the clinical lameness grade, especially in the forehand. Several horses with lameness grade ≤1/5 had asymmetry values greater than mentioned thresholds. The analysis of movement and weight-bearing asymmetry revealed that these objective variables did not necessarily act uniformly and therefore should be interpreted with caution

„Riding Soundness“ – die orthopädische Gesundheit von Reitpferden auf dem Prüfstand

Es ist unumstritten, dass lahmende Pferde nicht geritten werden sollten. Doch die Kompetenz von Pferdebesitzern, eine Lahmheit bei ihrem Pferd zuverlässig zu erkennen, wird zunehmend hinterfragt. Dieses Thema wurde jetzt in einer Studie genauer untersucht